In a groundbreaking study, researchers at Dana-Farber Cancer Institute have discovered that individuals with clonal hematopoiesis (CH), an age-related condition characterized by leukemia-related gene mutations in the blood, can safely serve as stem cell donors for cancer patients. This finding could significantly expand the pool of potential donors for stem cell transplants, a critical treatment for patients with high-risk hematologic malignancies.
Clonal hematopoiesis is common in individuals over the age of 40 and involves a small proportion of blood cells carrying mutations associated with leukemia. While high levels of these mutations can increase the risk of blood cancer and cardiovascular disease, the study found that stem cell transplants from donors with CH are generally safe and effective. Notably, transplants with a specific mutation in the DNMT3A gene were associated with better survival rates and a lower risk of relapse in recipients.
The study analyzed stem cell samples from 1,727 donors aged 40 and older, identifying CH in 22.5% of the donors. The most common mutations were in the DNMT3A and TET2 genes. Researchers found that 85% of CH clones from donor transplants successfully engrafted in recipients. Importantly, recipients of transplants with DNMT3A mutations had superior survival rates, attributed to a lower chance of disease recurrence.
This paradoxical discovery suggests that the increased immune system activity associated with DNMT3A mutations, which can be detrimental in non-transplant patients, may be beneficial in the context of stem cell transplantation by enhancing the immune response against cancer cells. The study also found no cases of leukemia development in recipients of transplants with DNMT3A or TET2 mutations, further supporting the safety of using donors with CH.
The findings challenge previous concerns about the risks of using older donors with CH and suggest that CH with a DNMT3A mutation should not be a reason to exclude potential donors. This research not only has the potential to broaden the donor pool for stem cell transplants but also opens new avenues for cancer treatment by combining immunotherapy agents with drugs targeting DNMT3A to mobilize a potent immune system attack on tumor cells.
